Numutkeun kana uji klinis multi-pusat anu dipimpin ku peneliti di Stanford University School of Medicine, jinis immunotherapy anyar sigana aman pikeun penderita kanker getih anu disebut lymphoma non-Hodgkin.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of lymphoma non-Hodgkin urang: diffuse large B- cell lymphoma and follicular lymphoma.
Dina 2010, panaliti anu dipimpin ku Irving Weissman, MD, sutradara Stanford Stem Cell Biology sareng Regenerative Medicine Institute, nunjukkeun yén ampir sadaya sél kanker katutup ku protéin anu disebat CD47, anu tiasa maénkeun "entong tuang kuring" Signal ka makrofag.
Weissman sareng kolega engké ngembangkeun hiji antibodi disebut Hu5F9-G4 nu meungpeuk protéin CD47 sarta nyorong makrofag ka engulf sél kanker. Rituximab mangrupikeun antibodi anu parantos ditingalikeun pikeun ngagedékeun sinyal positip "dahar kuring". Kombinasi rituximab na Hu5F-G4 saméméhna geus ditémbongkeun éféktif ngalawan kanker manusa dina model sasatoan, tapi ieu hasil diterbitkeun munggaran percobaan klinis tina terapi di manusa.
Tina 22 pasién anu ilubiung dina sidang, 11 pasién sacara nyata ngirangan kanker klinis, sareng 8 pasién parantos ngaleungitkeun sadaya tanda kanker. Tilu pasién anu sanés dina sidang henteu ngaréspon pangobatan sareng maot kusabab kamajuan panyakit. Panaliti niténan yén pamilon ngan ukur efek samping leutik.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
